Lunaphore launches LabSat in four major markets

With LabSat Research platform, Lunaphore offers an ultra-fast automated tissue-staining instrument for rapid immunohistochemistry (IHC) and immunofluorescence (IF). It utilizes Fast Fluidic Exchange microfluidic technology for rapid and uniform delivery of reagents to tissue samples. This enables accurate staining with improved protocol turnaround time.

In February 2020, Lunaphore received a strategic investment from PHC Holdings Corporation, the parent company of Epredia. Lunaphore and Epredia have now sealed a distribution agreement. Under the terms of this agreement, Epredia have been appointed the exclusive distributor of the LabSat Research platform in the US, UK and Germany, where Epredia will start to distribute the product in July 2020, as well as Japan, where commercialization will begin in 2021. In these countries, Epredia will also provide service for the Lunaphore instruments.

“Lunaphore is one of the most exciting players in tissue staining instruments and we believe that their technology has the potential to help revolutionize tissue analytics,” said Sandra Cummings, Vice President of Sales and Marketing for Epredia. “Their LabSat Research platform ideally complements our existing instruments and enables us to offer customers a more complete portfolio of immunohistochemistry staining solutions for research. We are excited to be able to bring this technology to researchers to support our mission to improve the lives of patients by enhancing precision cancer diagnostics.”

Lunaphore’s platform complements Epredia’s LabVision IHC portfolio to offer a complete line of precise, agile and flexible IHC solutions for research laboratories. LabVision IHC instruments and consumables are recognized for enabling standardized high throughput IHC staining and will be offered alongside Lunaphore’s solutions.

“This commercial partnership with Epredia is an exciting next step for Lunaphore, as it will expand our reach to key markets across the world, especially into the US”, said Ata Tuna Ciftlik, Lunaphore’s CEO. “By using Epredia’s global footprint and experience in the field, we will be able to empower more researchers with our technology and help them develop highly sophisticated next-generation tissue analytics tests.”

(Press release)